>
Akinwande Soji-Ojo
Swiss Pharma Nigeria Limited (SWIPHA) has commenced the process of recalling of all batches of Polyfort Suspension in stock over negative trend.
Polyfort Suspension is used to treat heartburn, indigestion, hyperacidity and flatulence.
The pharmaceutical company announced the recall of Polyfort Suspension in a statement dated April 27,2023, and signed by the Quality Manager, Olanrewaju Balaja, and Superintendent Pharmacist/BDD, Abbas Sambo.
In the statement titled, ‘Recall Exercise for Ployfort Suspension,’ which was addressed to its distributors and customers, SWIPHA said the recall was “on account of the result of ongoing stability study on batches LS222072, LS222073 and LS222074, showing a negative trend.”
“Kindly be informed that we are initiating an immediate recall for all batches of Polyfort Suspension in stock.
“This is on account of the result of ongoing stability study on batches LS222072, LS222073 and LS222074, showing a negative trend. We are currently carrying out further investigation on other batches.
“However, we are mandated to inform you within 24 to 48 hours. We are unable to wait for the outcome of this investigation, hence, the decision to recall all batches of Polyfort in your custody.
“Further sales of Polyfort Suspension in your custody should be stopped, and inventory segregated immediately. Also, contact customers to whom you sold Polyfort Suspension to return them back to you. All Polyfort stock (your stock and that of your customers) should be handed over to the Swipha medical or sales representatives assigned to you.
“We expect that all the packs of the concerned product are made ready for retrieval by the 5th of May 2023 and a corresponding credit note will be issued (covering your stock and that of your customer).
“The field force will inform you of developments as they evolve,” the statement read.